MedTrace Logo

Cost Analysis of Therapies for Severe Anemia

NCT06345469 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 640

Last updated 2024-04-03

No results posted yet for this study

Summary

The goal of this observational study is to learn about the costs that occur when participants with severe anemia are treated with blood transfusions or with patient blood management (PBM). PBM means that the body of the participant is stimulated to produce new blood by itself rather than receiving it from a blood donor, and to reduce blood losses.

The main question the study aims to answer is: Do participants treated with transfusions incur the same treatment costs than participants treated with PBM? And how much costs are this in relation to the lives saved by the therapy of severe anemia?

Conditions

  • Severe Anemia

Interventions

OTHER

Patient blood management (PBM)

PBM means the medical enhancement of the participants own hematopoietic reserve to treat anemia and to reduce the ill effects of disease and bleeding on hematopoiesis and homeostasis.

BIOLOGICAL

Allogeneic transfusion

transfusion of donor red cells

Sponsors & Collaborators

  • Marisa Eichner

    collaborator UNKNOWN

  • Helios Klinik Gotha/Ohrdruf

    lead OTHER

Principal Investigators

  • Petra Seeber, MD · HELIOS Klinikum Gotha

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2026-04-01
Completion
2026-05-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06345469 on ClinicalTrials.gov